New strategies for the treatment of metastatic bone disease

Clin Breast Cancer. 2007 Dec:8 Suppl 1:S35-45. doi: 10.3816/cbc.2007.s.010.

Abstract

The introduction of bisphosphonates represents an important advance in the care of patients with metastatic bone disease. Nonetheless, we remain unable to prevent metastatic bone destruction. This review will discuss several novel therapies, including inhibitors of receptor activator of nuclear factor-kappabeta, c-Src, mammalian target of rapamycin, cathepsin K, and alpha(5)beta(3) integrins, which could improve our control over this devastating complication.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Bone Density Conservation Agents / pharmacology
  • Bone Density Conservation Agents / therapeutic use*
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / secondary*
  • Bone Remodeling / drug effects
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / pathology
  • Cathepsin K
  • Cathepsins / therapeutic use
  • Diphosphonates / therapeutic use
  • Drugs, Investigational / pharmacology
  • Drugs, Investigational / therapeutic use*
  • Female
  • Humans
  • Integrin alpha Chains
  • Integrin beta Chains
  • Sirolimus / therapeutic use

Substances

  • Antineoplastic Agents
  • Bone Density Conservation Agents
  • Diphosphonates
  • Drugs, Investigational
  • Integrin alpha Chains
  • Integrin beta Chains
  • Cathepsins
  • CTSK protein, human
  • Cathepsin K
  • Sirolimus